Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Praxis Precision Medicines Inc (PRAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/22/2025: PRAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -17.65% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 767.50M USD | Price to earnings Ratio - | 1Y Target Price 97.67 |
Price to earnings Ratio - | 1Y Target Price 97.67 | ||
Volume (30-day avg) 407116 | Beta 2.67 | 52 Weeks Range 26.70 - 91.83 | Updated Date 05/22/2025 |
52 Weeks Range 26.70 - 91.83 | Updated Date 05/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-05-12 | When Before Market | Estimate -2.07 | Actual -3.29 |
Profitability
Profit Margin - | Operating Margin (TTM) -2868.84% |
Management Effectiveness
Return on Assets (TTM) -39.95% | Return on Equity (TTM) -63.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 440578241 | Price to Sales(TTM) 94.5 |
Enterprise Value 440578241 | Price to Sales(TTM) 94.5 | ||
Enterprise Value to Revenue 54.24 | Enterprise Value to EBITDA -6.86 | Shares Outstanding 20369000 | Shares Floating 15702041 |
Shares Outstanding 20369000 | Shares Floating 15702041 | ||
Percent Insiders 0.16 | Percent Institutions 116.76 |
Analyst Ratings
Rating 4.42 | Target Price 97.67 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Praxis Precision Medicines Inc
Company Overview
History and Background
Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. Founded in 2015, Praxis has advanced multiple programs into clinical development.
Core Business Areas
- Neurology: Development of therapies for epilepsy, including focal onset seizures and other rare epilepsies.
- Neuropsychiatry: Research and development of treatments for mood and anxiety disorders.
Leadership and Structure
The leadership team includes executives with experience in drug development and commercialization. The company operates with a structure focused on research and clinical development.
Top Products and Market Share
Key Offerings
- PRAX-19: An investigational antisense oligonucleotide targeting a specific subunit of the GABA-A receptor. Currently in clinical trials. Competitors: Multiple pharmaceutical companies developing antiseizure medications.
- PRAX-562: An investigational molecule targeting the neuronal hyperxcitability, or hyperexcitability, that causes neurological disorder symptoms. Currently in clinical trials. Competitors: Other pharmaceutical companies developing neurological disorder medications
Market Dynamics
Industry Overview
The pharmaceutical industry focused on CNS disorders is a large and competitive market with significant unmet medical needs.
Positioning
Praxis is positioned as a precision medicines company, targeting specific genetic and molecular drivers of CNS disorders. This personalized approach aims to improve treatment efficacy.
Total Addressable Market (TAM)
The TAM for CNS disorders is substantial. Praxis is positioned to address specific segments of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Precision medicine approach
- Experienced management team
- Diverse pipeline of drug candidates
- Focus on unmet medical needs
Weaknesses
- Clinical trial risks
- Limited commercialized products
- Reliance on partnerships and funding
- High R&D expenses
Opportunities
- Expansion of pipeline into new CNS disorders
- Partnerships with larger pharmaceutical companies
- Successful clinical trial outcomes
- Regulatory approvals and commercialization of products
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Patent expirations
Competitors and Market Share
Key Competitors
- EPIX
- AZN
- GSK
Competitive Landscape
Praxis is a smaller player compared to established pharmaceutical giants. Its competitive advantage lies in its precision medicine approach and focus on specific patient populations.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Praxis' growth is measured by advancements in clinical trials and expansion of the pipeline.
Future Projections: Future growth projections rely on successful clinical trial results and regulatory approvals. Analyst estimates are based on potential product sales.
Recent Initiatives: Recent initiatives include advancing PRAX-19 and PRAX-562 through clinical development, and focusing on strategic pipeline expansion.
Summary
Praxis Precision Medicines is a clinical-stage biopharmaceutical company with a focus on CNS disorders. While the company is still in the development phase and faces significant clinical trial risks, it has a compelling precision medicine approach and an experienced team. Future success hinges on positive clinical trial outcomes and regulatory approvals. The company needs to maintain its cash runway and manage its R&D expenses effectively.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
EPIX
ESSA Pharma Inc
EPIX
ESSA Pharma Inc
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on publicly available information, and its accuracy cannot be guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Praxis Precision Medicines Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-16 | President, CEO & Director Mr. Marcio Silva De'Souza M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | Website https://praxismedicines.com |
Full time employees 116 | Website https://praxismedicines.com | ||
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
